Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00537043 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00537043 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 24 participants.
The verdict
NCT00537043, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Carvedilol controlled release is a marketed drug to treat high blood pressure. This study is to compare carvedilol controlled release to carvedilol controlled release plus lisinopril (fixed-dose combination) after repeat dosing in patients with high blood pressure. This is to make sure that when carvedilol controlled release is given with lisinopril it acts the same in the body as when given alone. The study will also assess the safety and tolerability of the fixed-dose combination.
Interventions
- DRUG SK&F-105517 (COREG CR FDC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00537043
The ClinicalTrials.gov registry entry for NCT00537043 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SK&F-105517 (COREG CR FDC) is the first listed.
NCT00537043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00537043 about?
NCT00537043 is a clinical study titled "A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure". Carvedilol controlled release is a marketed drug to treat high blood pressure. This study is to compare carvedilol controlled release to carvedilol controlled release plus lisinopril (fixed-dose combination) after repeat dosing in patients with high blood pressure. This is to make sure that when car...
What is the current status of trial NCT00537043?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2007-10. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00537043?
The interventions under investigation include: SK&F-105517 (COREG CR FDC) (DRUG).
Who is sponsoring clinical trial NCT00537043?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.